Emergent Biosolutions (EBS)
(Real Time Quote from BATS)
$10.76 USD
+0.87 (8.80%)
Updated Jul 12, 2024 02:24 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
EBS 10.76 +0.87(8.80%)
Will EBS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EBS
Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Other News for EBS
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
Key Takeaways From Emergent BioSolutions Analyst Ratings
7 Top Stocks Under $10: June 2024 Edition